Ryoichi Maenosono

Ryoichi Maenosono

Auto-generated profile, based on publicly available information

Ryoichi Maenosono

Department of Urology Osaka Medical and Pharmaceutical University Hospital Osaka Japan

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 October 2023 in American Journal of Transplantation
Verified
Journal Article
Open access
JIJasper Iske
Jasper Iske
MRMaximilian J. Roesel
Maximilian J. Roesel
FMFriederike Martin
Friederike Martin
ASAndreas Schroeter
Andreas Schroeter
TMTomohisa Matsunaga
Tomohisa Matsunaga
STStefan G. Tullius
Stefan G. Tullius
In clinical organ transplantation, donor and recipient ages may differ substantially. Old donor organs accumulate senescent cells that have the capacity to induce senescence in naïve cells. We hypothesized that the engraftment of old organs may induce senescence in younger recipients, promoting age-related pathologies. When performing isogeneic cardiac transplants between age-mismatched C57BL/6 old donor (18 months) mice and young and middle-aged C57BL/6 (3- or 12- month-old) recipients , we observed augmented frequencies of senescent cells in draining lymph nodes, adipose tissue, livers, and hindlimb muscles 30 days after transplantation. These observations went along with compromised physical performance and impaired spatial learning and memory abilities. Systemic levels of the senescence-associated secretory phenotype factors, including mitochondrial DNA (mt-DNA), were elevated in recipients. Of mechanistic relevance, injections of mt-DNA phenocopied effects of age-mismatched organ transplantation on accelerating aging. Single treatment of old donor animals with senolytics prior to transplantation attenuated mt-DNA release and improved physical capacities in young recipients. Collectively, we show that transplanting older organs induces senescence in transplant recipients, resulting in compromised physical and cognitive capacities. Depleting senescent cells with senolytics, in turn, represents a promising approach to improve outcomes of older organs.

15 July 2021 in Cancers
Verified
Journal Article
Open access
PDF file
TUTaizo Uchimoto
Taizo Uchimoto
KKKazumasa Komura
Kazumasa Komura
WFWataru Fukuokaya
Wataru Fukuokaya
TKTakahiro Kimura
Takahiro Kimura
KTKazuhiro Takahashi
Kazuhiro Takahashi
HAHaruhito Azuma
Haruhito Azuma
Pembrolizumab has emerged as the new standard of care in patients with platinum-refractory metastatic urothelial carcinoma (mUC), whereas the optimal risk stratification to predict survival outcomes is still controversial. We examined a risk model for overall survival (OS) in mUC treated with pembrolizumab using our multi-institutional dataset (212 patients). The median age was 72 years old. Median OS from the initiation of pembrolizumab treatment was 11.7 months. The objective response rate (ORR) was 26.4%. On multivariate analysis, multiple metastatic sites and an NLR > 3.50 at the initiation of pembrolizumab treatment were identified as independent predictors for OS. We next developed a risk model using those two predictors. Patients without any factors were assigned to the favorable-risk group (26.5%). Patients with either factor and both factors were assigned to the intermediate-risk group (44.3%), and poor-risk group (29.2%), respectively. Kaplan–Meier curves showed clear discrimination of OS among the risk groups (p < 0.001). The ORR in each group was 35.7% in the favorable-risk group, 27.7% in the intermediate-risk group, and 17.7% in the poor-risk group. Given that the model can be concisely determined at the initiation of pembrolizumab treatment, physicians may be encouraged to consider the risk group for daily practice.

14 September 2019 in International Journal of Urology
Verified
Journal Article
Closed access
PDF file
RMRyoichi Maenosono
Ryoichi Maenosono
KUKohei Unagami
Kohei Unagami
YKYoichi Kakuta
Yoichi Kakuta
MFMiyuki Furusawa
Miyuki Furusawa
MOMasayoshi Okumi
Masayoshi Okumi
KTKazunari Tanabe
Kazunari Tanabe

30 January 2021 in Cancers
Verified
Journal Article
Open access
PDF file
TUTaizo Uchimoto
Taizo Uchimoto
KKKazumasa Komura
Kazumasa Komura
WFWataru Fukuokaya
Wataru Fukuokaya
TKTakahiro Kimura
Takahiro Kimura
KTKazuhiro Takahashi
Kazuhiro Takahashi
HAHaruhito Azuma
Haruhito Azuma
The identification of early or primary resistance to androgen signaling inhibitors (ASIs) is of great value for the treatment of metastatic castration-resistant prostate cancer (mCRPC). This study evaluates the predictive value of prostate-specific antigen (PSA) response at dour weeks of first-line ASIs treatment for mCRPC patients. A total of 254 patients treated with ASIs (abiraterone acetate: AA and enzalutamide: Enz) at the first-line treatment are retrospectively analyzed. Patients are stratified according to the achievement of >30% PSA decline at 4 and 12 weeks from the treatment initiation. At four weeks of the treatment, 157 patients (61.8%) achieved >30% PSA decline from the baseline. Thereafter, 177 patients (69.7%) achieved >30% PSA decline at 12 weeks of the treatment. A multivariate analysis exhibits >30% PSA decline at four weeks as an independent predictor for overall survival (OS). We note that 30 of 97 (30.9%) patients who did not achieve >30% PSA decline at four weeks consequently achieved >30% PSA decline at 12 weeks, and had a comparable favorable three years OS rate as the 147 patients achieving >30% PSA decline at both 4 and 12 weeks. To identify the variables that discriminate the patient survival in 97 patients without achieving >30% PSA decline at four weeks, a multivariate analysis is performed. The duration of androgen deprivation therapy before CRPC ≤ 12 months and Eastern Cooperative Oncology Group Performance Status ≥ 1 are identified as independent predictors for shorter OS for those patients. These data offer a concept of early treatment switch after four weeks of first-line ASIs when not observing >30% PSA decline at four weeks—particularly in patients with a modest effect of ADT and poor performance status.

19 August 2025 in International Journal of Urology
Verified
Journal Article
Open access
TNTakuhisa Nukaya
Takuhisa Nukaya
KTKiyoshi Takahara
Kiyoshi Takahara
STShingo Toyoda
Shingo Toyoda
LILan Inoki
Lan Inoki
WFWataru Fukuokaya
Wataru Fukuokaya
RSRyoichi Shiroki
Ryoichi Shiroki
Objectives: We aimed to evaluate overall survival (OS) and determine the optimal timing of cytoreductive nephrectomy (CN) in patients with metastatic renal cell carcinoma (mRCC) receiving immune checkpoint inhibitor (ICI)‐based therapy. Methods: This retrospective study reviewed medical records of 447 patients with mRCC treated with ICI at multiple Japanese institutions between January 2018 and August 2023. From this cohort, 178 patients with lymph node or distant metastases received either cytoreductive nephrectomy (CN group; n = 72) or ICI therapy without cytoreductive nephrectomy (non‐CN group; n = 106) as first‐line treatment. Results: Median progression‐free survival was 15.7 months, and median overall survival was 58.1 months. CN significantly improved OS, with the CN group's median OS not reached, compared to 29.6 months in the non‐CN group ( p = 0.01). Deferred CN also showed improved survival outcomes. Poor prognostic factors for immediate CN included International Metastatic Renal Cell Carcinoma Database Consortium poor risk, sarcomatoid differentiation, and a high neutrophil‐to‐lymphocyte ratio. Conclusions: We developed a prognostic model to guide patient selection for CN, emphasizing the need for personalized treatment strategies.

20 May 2026 in International Journal of Urology
Verified
Journal Article
Open access
STShuichi Tatarano
Shuichi Tatarano
Makito MiyakeMakito Miyake
Makito Miyake
YOYu Osaki
Yu Osaki
KDKei Daizumoto
Kei Daizumoto
KWKoichiro Wada
Koichiro Wada
HEHideki Enokida
Hideki Enokida
Objectives: Penile cancer is a rare malignancy, and multicenter data evaluating prognostic biomarkers in the Japanese population are limited. This study aimed to assess the prognostic significance of pretreatment blood‐based biomarkers in patients with penile cancer. Methods: We conducted a multicenter retrospective cohort study including 111 patients with penile cancer treated between January 2005 and December 2023 at ten institutions participating in the West Japan Uro‐oncology Collaboration Group. Cancer–specific survival (CSS) was analyzed using the Kaplan–Meier method and Cox proportional hazards model. Receiver operating characteristic analyses were performed to determine optimal cutoff values for the neutrophil‐to‐lymphocyte ratio (NLR), platelet‐to‐lymphocyte ratio (PLR), and squamous cell carcinoma antigen (SCC‐Ag). A composite biomarker score was calculated based on the number of elevated biomarkers. Results: The 5‐year overall survival and CSS rates were 71.1% and 77.4%, respectively. In univariate analyses, elevated PLR, elevated SCC‐Ag, and higher composite biomarker scores were significantly associated with poorer CSS. In multivariate analysis, advanced clinical nodal status (≥ cN2) and distant metastasis (cM1) remained independent predictors of CSS, whereas blood‐based biomarkers did not retain independent prognostic significance after adjustment for established clinicopathological factors. Kaplan–Meier analyses demonstrated significantly worse CSS in patients with high PLR, high SCC‐Ag levels, and higher composite biomarker scores. Conclusions: Pretreatment blood‐based biomarkers, particularly PLR and SCC‐Ag, are associated with prognosis in penile cancer. Although they did not retain independent prognostic factors after adjustment, these biomarkers may provide complementary prognostic information and help identify high‐risk patients in clinical practice.